ClinicalTrials.gg
Active, not recruitingNCT07024212Updated Jul 7, 2026

Phase II Study Evaluating the Efficacy and Safety of DR10624 Injection in MASLD and MetALD Subjects

A Phase 2 interventional study of DR10624 Injection and Placebo in MASLD, sponsored by Zhejiang Doer Biologics Co., Ltd.. Active, not recruiting at 4 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by Zhejiang Doer Biologics Co., Ltd. (part of Huadong Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 142 studies in Non-alcoholic Fatty Liver Disease with a site in China — 42 open to participants now, 54 under way, 5 of them phase 3. Non-alcoholic Fatty Liver Disease · China.

Planned enrollment
46th of 89
110 · median 112
Started
2025
with 9 others
Phase 2
20 of 142
3 open now
Primary completion
2026-06
later than 19 of 53 live
Registered
126th of 142
by date

Among the 142 studies in Non-alcoholic Fatty Liver Disease with a site in China, this one is the 46th largest by planned enrollment of the 89 interventional ones that give a count, is one of 10 that started in 2025, is one of 20 in phase 2, reaches primary completion later than 19 of the 53 other live ones, and was the 126th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

42 of the 142 studies in Non-alcoholic Fatty Liver Disease with a site in China are open now. Recruiting first, the newest first:

37 more — sign in →

All 42 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 142 studies in Non-alcoholic Fatty Liver Disease with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase II clinical trial that consists of two parts. The primary objective of Part 1 is to assess the preliminary efficacy of DR10624 Injection in MASLD subjects at high risk of liver fibrosis. The secondary objectives are to assess the safety and tolerability, PK profiles, and immunogenicity of DR10624 Injection in these subjects. The exploratory objectives are to assess the efficacy of DR10624 Injection in these subjects using LSM assessed by MRE, and its impact on Lp(a) and body composition.The primary objective of Part 2 is to assess the safety and tolerability of DR10624 Injection in MetALD subjects at high risk of liver fibrosis. This clinical trial is currently only conducting Part 1 of the study.

03

Conditions studied

  • MASLD

Keywords

  • NASH
  • MASH
  • NAFLD
  • MAFLD
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who have signed the form before the trial, and fully understood the trial content, process and possible adverse reactions;
  2. Males or females aged 18-75 years (inclusive) at the time of signing the informed consent form;
  3. LFC ≥ 10% assessed by MRI-PDFF (MRI-PDFF results that are obtained at the study site within 6 weeks prior to randomization are acceptable);
  4. Screening FibroScan® with liver stiffness (LSM): ≥ 8 Kpa, and \< 15 Kpa;
  5. Have a (BMI) between 25.0 and 40.0 kg/m2 (inclusive) at screening;
  6. Less than 5% change in body weight within 6 months prior to randomization;
  7. If there is a history of type 2 diabetes, a stable treatment regimen must be maintained for at least 12 weeks prior to screening;
  8. Females of and males must agree to use effective during the study and for a specified period after the last dose of the medicinal product (2 months for females, 3 months for males).

Exclusion criteria

Exclusion Criteria:

  1. Presence of cirrhosis on liver or imaging results, or have a history of cirrhosis;
  2. Other causes of liver disease based on medical history and/or laboratory tests;
  3. Previous (within 5 years before randomization) or planned (during the study period) obesity treatment with metabolic surgery or device-based therapy subjects with reversible weight-loss devices removed more than 12 months prior to randomization are eligible;
  4. Type 1 diabetes;
  5. History of within the last 5 years prior to screening, or malignancies that occurred more than 5 years ago but which are still currently active. Local squamous cell carcinoma of the skin or cervical intraepithelial neoplasia that has been cured without signs of recurrence is acceptable;
  6. Presence of severe or uncontrolled underlying disease that, in the opinion of the investigator, renders the subject unsuitable for treatment with the medicinal product or unable to complete study, or is likely to interfere with the evaluation of study results;
  7. Subjects who have a history of bone trauma, fracture, or bone surgery within 2 months prior to screening, or concomitant bone disorders such as osteomalacia or known, untreated severe vitamin D deficiency (serum 25-hydroxyvitamin D ≤5 ng/mL); or a T-score ≤-2.5 for bone mineral density measured by DXA in the axial skeleton (lumbar vertebrae 1-4, femur neck, or total hip);
  8. Subjects who have a history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, or a related family history;
  9. Any significant abnormal laboratory findings from screening to randomization;
  10. Subjects who have used or plan to use the following medications that may cause steatosis/steatohepatitis cumulatively for ≥4 weeks within 24 weeks prior to randomization or during the study: amiodarone, methotrexate, systemic (dose >5 mg/day prednisone equivalent), estrogens (dose greater than that used for hormone replacement therapy or ), tetracyclines, tamoxifen, anabolic steroids, valproic acid, or other drugs known to have hepatotoxicity, etc.;
  11. Use of any of the following medications cumulatively for ≥4 weeks within 24 weeks prior to randomization or planned during the study: high-dose vitamin E (daily dose >400 IU), obeticholic acid, pioglitazone, berberine, or thyroid hormones (subjects with hypothyroidism who have received stable replacement therapy for at least 3 months prior to randomization are acceptable), etc.;
  12. Use of antidiabetic drugs other than metformin, sulfonylureas, alpha-glucosidase inhibitors, glucokinase activators (GKA), or sodium-glucose cotransporter 2 (SGLT-2) inhibitors within 12 weeks prior to screening or planned during the study;
  13. Use of Schisandra preparations (e.g., bifendate, bicyclol) within 6 weeks prior to randomization, or use of the following hepatoprotective drugs (including but not limited to reduced glutathione, glucuronolactone, glycyrrhizic acid preparations, polyene phosphatidylcholine, ursodeoxycholic acid, nicotinamide, liver-protecting tablets, silymarin, etc.) or other hepatoprotective Chinese proprietary medicines or health products within 2 weeks prior to randomization; or planned use of such drugs during the study;
  14. Use of weight-loss drugs such as orlistat or GLP-1 receptor agonists, or other drugs with the same target as the investigational medicinal product [e.g., fibroblast growth factor-21 (FGF21) analogs, glucagon receptor (GCGR) agonists, etc.], within 6 weeks prior to screening or planned during the study;
  15. Use of anti-tumor necrosis factor α (TNF-α) drugs, such as adalimumab or etanercept, etc., within 6 weeks prior to screening or planned during the study;
  16. Known or suspected intolerance or to the investigational medicinal product or any of its ; or known intolerance or hypersensitivity to drugs with the same target (e.g., FGF21 analogs, GLP-1 receptor agonists, GCGR agonists, etc.);
  17. Subjects who have participated in clinical trials of other drugs and used investigational medicinal product within 12 weeks or 5 half-lives (whichever is longer) prior to screening, or those who have participated in medical device or vaccine clinical trials;
  18. Alcohol consumption for at least 12 consecutive weeks within 1 year prior to screening, defined as any of the following: > 210 grams of ethanol per week for males on average, > 140 grams per week for females on average;
  19. History of drug abuse or use of illicit drugs within 3 years prior to screening;
  20. Pregnant or breastfeeding females, or females with a positive serum pregnancy test prior to randomization;
  21. Subjects who, in the investigator's opinion, are otherwise not suitable for participation in this clinical trial.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    Cohort 1:DR10624 injection/Placebo (SC, qw)

    DR10624 injection/Placebo (SC, qw)

    Drug: DR10624 Injection · Drug: Placebo

  • Experimental
    Cohort 2:DR10624 injection/Placebo (SC, qw)

    DR10624 injection/Placebo (SC, qw)

    Drug: DR10624 Injection · Drug: Placebo

  • Experimental
    Cohort 3:DR10624 injection/Placebo (SC, qw)

    DR10624 injection/Placebo (SC, qw)

    Drug: DR10624 Injection · Drug: Placebo

  • Experimental
    Cohort 4:DR10624 injection/Placebo (SC, qw)

    DR10624 injection/Placebo (SC, qw)

    Drug: DR10624 Injection · Drug: Placebo

  • Experimental
    Cohort 5:DR10624 injection/Placebo (SC, qw)

    DR10624 injection/Placebo (SC, qw)

    Drug: DR10624 Injection · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Changes of LFC

    Relative percentage changes (%) of Liver Fat Content (LFC) from baseline to Week 12, assessed by MRI-PDFF.

    Time frame: From baseline to Week 12

Secondary outcomes

  1. Changes of Controlled Attenuation Parameter (CAP)

    Changes of CAP from baseline to Week 12, assessed by FibroScan® VCTE.

    Time frame: From baseline to Week 12

  2. Changes of Liver Stiffness Measurement (LSM)

    Changes of LSM from baseline assessed by FibroScan® VCTE.

    Time frame: From baseline to Week 12

  3. Changes of LFC

    Changes of LFC from baseline to Week 12, assessed by MRI-PDFF.

    Time frame: From baseline to Week 12

  4. Proportion of subjects achieving a relative reduction of LFC

    Proportion of subjects who achieve a relative reduction of LFC by ≥30%, ≥50%, or ≥70% from baseline to Week 12.

    Time frame: From baseline to Week 12

  5. Proportion of subjects with LFC <5%

    Proportion of subjects with LFC \<5% after 12 weeks of treatment.

    Time frame: From baseline to Week 12

  6. Changes of liver enzymes

    Changes of liver enzymes from baseline to Week 16.

    Time frame: From baseline to Week 16

  7. Proportion of subjects with ≥17 U/L reduction of ALT

    Proportion of subjects with ≥17 U/L reduction of ALT from baseline to Week 16.

    Time frame: From baseline to week 16

  8. Changes of glucose metabolism-related parameters

    Changes of glucose metabolism-related parameters from baseline to Week 12.

    Time frame: From baseline to Week 12

  9. Changes of lipid profiles

    Changes of lipid profiles from baseline to Week 16.

    Time frame: From baseline to Week 16

  10. Changes of body weight

    Changes of body weight from baseline to Week 16

    Time frame: From baseline to Week 16

  11. Changes of BMI

    Changes of BMI from baseline to Week 16, BMI = weight (kg)/height2 (m2), height is measured only at screening, while weight is measured at each corresponding visit.

    Time frame: From baseline to Week 16

  12. Changes of hip circumference

    Changes of hip circumference from baseline to Week 16. The hip circumference should be recorded in cm, accurate to mm (e.g., 96.6 cm).

    Time frame: From baseline to Week 16

  13. Changes of waist-to-hip ratio

    Changes of waist-to-hip ratio from baseline to Week 16 Waist-to-hip ratio = waist circumference (cm) / hip circumference (cm).

    Time frame: From baseline to Week 16

  14. Changes of fibrosis biomarkers

    Changes from baseline in fibrosis biomarkers.

    Time frame: From Baseline to Week 12

  15. Changes of hepatic inflammation markers

    Changes of hepatic inflammation markers from baseline to Week 12

    Time frame: From baseline to week 12

  16. Analysis of Safety Endpoints

    Safety parameters from baseline to Week 16

    Time frame: From baseline to week 16

  17. Immunogenicity analysis

    Assess the immunogenicity from baseline to Week 16

    Time frame: From baseline to Week 16

  18. Pharmacokinetics profiles of DR10624 Injection

    Measurement of DR10624 plasma concentration and calculation of C trough.

    Time frame: From baseline to Week 12

07

Study locations

4 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2025 to primary completion in Jun 2026, 13 months.

Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 13 months is below that.

Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2025
First posted
Jun 17, 2025
StartActual
Apr 22, 2025
Primary completionActual
Jun 18, 2026
CompletionEst.
Sep 30, 2026
Last update
Jul 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07024212
Responsible party
Sponsor
First posted
Jun 17, 2025
Start date
Apr 22, 2025
Primary completion
Jun 18, 2026
Completion
Sep 30, 2026 (estimated)
Last update
Jul 7, 2026

Study contacts

Vincent Wai-Sun Wong, M.D.
study chair · Prince of Wales Hospital, The Chinese University of Hong Kong
Junping Shi, M.D.
principal investigator · The Affiliated Hospital of Hangzhou Normal University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: DR10624

Start the discussion